Provectus Pharmaceuticals Inc. (PVCT.OB) Delivers Favorable Oncology Treatment; Presents Data to 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers
Provectus Pharmaceuticals Inc. is a development-stage biopharmaceutical study focused on oncology and dermatology therapies. The company recently announced that the results of its phase II trial showed comparable trends to phase I survival data for 20 subjects with metastatic melanoma. The one-year overall survival data of its lead oncology agent PV-10 showed longer overall and disease specific survival for subjects that were responsive to the agent, relative to those who did not experience a robust response. In addition, several subjects experienced spontaneous regression of untreated tumors after PV-10 treatment of other tumors. The company also announced that Professor John F.…